press
need
develop
new
antivir
abstract
press
need
develop
new
antivir
treatment
drug
current
avail
half
aim
remaind
target
six
virus
demand
led
emerg
possibl
peptid
therapi
current
clinic
trial
advanc
understand
antivir
potenti
natur
occur
host
defenc
peptid
highlight
potenti
whole
new
class
molecul
consid
antivir
therapeut
cation
host
defenc
peptid
defensin
cathelicidin
import
compon
innat
immun
antimicrobi
immunomodulatori
capabl
recent
year
also
shown
natur
broadspectrum
antivir
envelop
nonenvelop
virus
includ
influenza
viru
respiratori
syncyti
viru
herp
simplex
viru
review
antivir
properti
sever
famili
host
peptid
potenti
inform
design
novel
therapeut
viral
diseas
lead
caus
morbid
mortal
worldwid
particularli
children
yet
develop
effect
therapi
slow
particular
progress
hamper
fact
major
antivir
drug
specif
one
viru
current
approach
expens
requir
rapid
identif
viru
therapi
initi
stage
develop
involv
enorm
redund
research
effort
also
result
effort
concentr
virus
antivir
drug
far
approv
us
food
drug
administr
fda
almost
half
target
remain
half
use
treatment
hepat
b
viru
hbv
herp
simplex
viru
hsv
varicellazost
viru
vzv
cytomegaloviru
cmv
influenza
iav
hepat
c
viru
hcv
infect
factor
combin
rate
develop
drug
resist
mean
urgent
need
new
broaderspectrum
intervent
strategi
therefor
excit
recent
year
new
class
antivir
therapeut
peptid
emerg
peptidebas
intervent
strategi
virus
current
variou
stage
clinic
trial
peptidebas
strategi
propos
costeffect
peptid
low
molecular
weight
rapid
elimin
follow
treatment
low
level
side
effect
excit
current
area
advanc
understand
antivir
properti
natur
occur
cation
host
defenc
peptid
chdp
capac
inform
design
novel
synthet
antivir
analogu
review
give
overview
antivir
activ
chdp
consid
potenti
develop
broadspectrum
antivir
therapeut
defenc
infect
emphasis
conserv
across
plant
insect
reptil
bird
fungi
mammal
two
major
famili
chdp
defensin
cathelicidin
defensin
cation
amphipath
peptid
gener
prepropeptid
via
proteolysi
categoris
within
three
subfamili
b
h
defensin
first
characteris
natur
peptid
antibiot
discoveri
adefensin
granul
neutrophil
adefensin
famili
identifi
rang
higher
eukaryot
includ
primat
mice
rat
guinea
pig
rabbit
compris
six
distinct
peptid
human
human
neutrophil
peptid
hnp
human
defensin
hd
express
five
defa
gene
triplestrand
bsheet
core
stabilis
three
intramolecular
disulphid
bond
made
first
prepropeptid
proteolyt
cleav
activ
form
case
key
proteas
trypsin
produc
mainli
neutrophil
compris
total
neutrophil
protein
neutrophil
precursor
bone
marrow
also
describ
nk
cell
b
cell
cd
cell
macrophag
immatur
dendrit
cell
acquir
neutrophil
releas
activ
hnp
neutrophil
azurophil
granul
induc
rang
stimuli
includ
chemokin
fc
gamma
receptor
cross
link
pma
tlr
stimul
contrast
express
paneth
cell
small
intestin
epitheli
cell
femal
genit
tract
interestingli
although
mice
express
larg
number
intestin
adefensin
cryptdin
contrast
human
express
adefensin
neutrophil
adefensin
welldescrib
broad
spectrum
antimicrobi
activ
gramposit
neg
organ
vitro
cation
hydrophob
shown
key
determin
properti
cation
charg
propos
enabl
interact
net
neg
charg
surfac
gramneg
bacteria
teichoic
acid
gramposit
organ
amphipath
structur
enabl
insert
disrupt
bacteri
membran
lead
lysi
cell
addit
variou
adefensin
describ
addit
nonmicrobicid
properti
includ
chemotaxi
effector
cell
innat
adapt
immun
system
inhibit
macrophag
proinflammatori
cytokin
modul
intestin
microbiom
format
protect
peptid
nanonet
bdefensin
famili
contain
member
human
mice
wide
express
across
mani
speci
particular
defensin
found
bird
close
homologu
present
snake
platypu
sea
anemon
also
triplestrand
bsheet
protein
differ
afamili
member
organis
arrang
three
disulphid
bond
well
characteris
human
bdefensin
human
bdefensin
hbd
express
epitheli
cell
monocyt
macrophag
macrophagederiv
dc
encod
express
constitut
wherea
express
upregul
respons
variou
inflammatori
stimuli
includ
microb
tlr
nod
protein
proinflammatori
cytokin
bdefensin
also
describ
broadspectrum
antimicrobi
activ
vitro
potenc
vari
differ
famili
member
interestingli
weak
microbicid
properti
recent
shown
greatli
enhanc
upon
reduct
disulphid
bond
although
rel
mild
phenotyp
found
mous
model
defici
redund
multigen
famili
may
respons
observ
addit
bdefensin
describ
rang
immunomodulatori
properti
includ
chemotaxi
memori
cell
macrophag
immatur
dendrit
cell
enhanc
wound
heal
modul
inflammatori
cytokin
respons
capac
promot
suppress
inflamm
differ
set
hdefensin
circular
octadecapeptid
circular
peptid
mammalian
origin
form
splice
two
nonapeptid
contribut
three
cystein
seri
disulphid
bond
matur
peptid
three
hdefensin
found
leukocyt
rhesu
macaqu
name
although
six
rna
transcript
homolog
rtd
found
human
bone
marrow
contain
prematur
stop
codon
prevent
express
howev
artifici
construct
peptid
base
pseudogen
call
retrocyclin
studi
respect
function
therapeut
potenti
shown
kill
escherichia
coli
way
adefensin
permeabilis
membran
cathelicidin
famili
quit
distinct
defensin
cathelicidin
defin
conserv
cathelin
domain
variabl
ctermin
region
proteolyt
cleav
produc
matur
function
peptid
rang
structur
form
differ
famili
member
contrast
extens
defensin
famili
human
mice
rat
rabbit
express
singl
cathelicidin
wherea
multipl
cathelicidin
found
speci
eg
protegrin
pig
sole
human
cathelicidin
human
cation
antimicrobi
peptid
kda
encod
camp
gene
cleav
proteinas
activ
form
cation
amphipath
peptid
kda
ahel
structur
store
neutrophilspecif
granul
induc
epitheli
cell
macrophag
leukocyt
lesser
extent
detect
rang
bodi
fluid
includ
airway
surfac
liquid
plasma
urin
breast
milk
sweat
upregul
respons
infecti
inflammatori
signal
wound
express
increas
vitamin
metabolit
compound
butyr
welldocu
antibacteri
potenti
howev
studi
presenc
physiolog
concentr
cation
serum
high
minimum
inhibitori
concentr
compar
level
describ
vivo
mice
defici
mcramp
encod
camp
gene
orthologu
camp
increas
suscept
infect
multipl
system
includ
skin
intestin
tract
lung
although
model
clearli
demonstr
critic
role
cathelicidin
host
defenc
infect
remain
unclear
extent
due
microbicid
modulatori
properti
peptid
shown
broad
rang
immunomodulatori
inflammomodulatori
properti
includ
chemotact
activ
neutrophil
monocyt
cell
modul
cytokin
product
effect
dendrit
cell
differenti
function
promot
wound
heal
angiogenesi
modul
cell
death
although
field
antimicrobi
peptid
research
domin
evalu
antibacteri
activ
peptid
earli
studi
evalu
antivir
potenti
human
adefensin
show
promis
follow
increas
level
research
interest
fig
first
paper
detail
antivir
role
publish
year
ago
describ
inhibit
number
virus
includ
hsv
type
cytomegaloviru
vesicular
stomat
viru
vitro
particular
demonstr
direct
antivir
activ
temperatureand
phdepend
manner
inhibit
serum
interestingli
less
sensit
inhibitori
effect
cation
broadli
studi
antibacteri
properti
subsequ
found
activ
approxim
log
decreas
lgml
prevent
viral
bind
either
glycoprotein
b
heparan
sulphat
primari
receptor
hsv
bind
capac
found
primarili
determin
peptid
sequenc
rather
net
cation
charg
lectinlik
properti
like
key
glycoprotein
bind
function
interestingli
defensin
bound
viral
envelop
gb
also
found
effect
prevent
infect
ad
viral
entri
even
h
postinfect
suggest
addit
later
stage
effect
viral
replic
furthermor
cumul
effect
observ
repeat
applic
peptid
reduc
infect
hsv
greater
log
lgml
featur
make
adefensin
consider
interest
potenti
exogen
vagin
microbicid
proof
concept
studi
mice
demonstr
protect
hsv
follow
gelbas
applic
adefensin
demonstr
directli
inactiv
observ
reduc
cytopathogen
cell
line
although
confus
exist
follow
retract
paper
propos
adefensin
key
compon
antivir
factor
caf
worth
note
retract
relat
sourc
adefensin
probabl
import
cell
cocultur
cell
properti
peptid
call
question
inde
potenti
adefensin
treat
hiv
reinforc
found
breast
milk
adefensin
concentr
significantli
associ
decreas
risk
intrapartum
postnat
hiv
transmiss
recent
studi
demonstr
multipl
step
entri
viru
cell
disrupt
peptid
shown
bind
env
glycoprotein
viru
thu
induc
downregul
block
interact
env
coreceptor
target
particular
conform
env
also
inhibit
late
fusion
step
bind
high
affin
howev
much
weaker
binder
potent
inhibitor
mean
aspect
direct
inhibit
current
entir
clear
mechanist
studi
shown
also
inhibit
step
follow
revers
transcript
integr
inhibit
pkc
activ
pkc
import
hiv
replic
upregul
transcript
nfjb
activ
tat
phosphoryl
well
regul
fusion
assembl
virion
worth
note
studi
direct
effect
viru
particl
occur
absenc
serum
presenc
mechan
inhibit
effect
instead
host
cell
result
inhibit
replic
viru
defensin
also
stimul
antivir
state
cell
promot
secret
chemokin
macrophag
upregul
chemokin
also
contribut
inhibit
hiv
competit
receptor
potenti
issu
use
defensin
topic
antivir
treatment
despit
chdp
includ
defensin
requir
vitro
antihiv
activ
vagin
fluid
healthi
women
defensin
may
also
caus
immun
activ
subsequ
loss
cell
apoptosi
may
indirectli
enhanc
hiv
transmiss
particular
known
chemotact
dc
induc
infiltr
dc
cultur
hpvtransform
keratinocyt
subsequ
immun
activ
addit
produc
cervicovagin
epitheli
cell
present
lgml
vagin
fluid
healthi
women
enhanc
hiv
infect
vitro
promot
viru
attach
target
cell
thu
balanc
effect
remain
determin
adefensin
also
found
high
concentr
inflam
lung
gener
interest
potenti
activ
respiratori
virus
abund
antimicrobi
peptid
airway
fluid
upregul
follow
infect
inflamm
produc
immigr
neutrophil
airway
epitheli
cell
daher
et
al
first
describ
antivir
effect
wsn
strain
iav
vitro
show
fairli
modest
approxim
log
reduct
lgml
properti
later
confirm
strain
iav
decreas
infect
approxim
log
lgml
fluoresc
focu
assay
infect
peptid
shown
activ
haemagglutinin
inhibit
assay
induc
aggreg
iav
interestingli
hnp
aggreg
viral
strain
much
higher
strain
greater
surfac
glycosyl
neutralis
activ
hnp
greater
suggest
reduc
carbohydr
attach
envelop
protein
allow
greater
interact
defensin
howev
direct
effect
iav
viral
particl
found
impact
viral
growth
infect
cultur
maxim
antivir
effect
studi
log
lgml
rang
cell
line
requir
interact
eukaryot
cell
infect
continu
presenc
peptid
cultur
system
nevertheless
contrast
pretreat
viru
pretreat
cell
induc
protect
suggest
predomin
mechan
action
cellmedi
propos
consequ
hnpmediat
inhibit
pkc
activ
essenti
endosom
traffick
iav
capac
adefensin
protect
iav
lost
linearis
analogu
addit
effect
iav
infect
epitheli
cell
approxim
lgml
enhanc
uptak
iav
neutrophil
follow
preincub
either
cell
viru
defensin
howev
modul
neutrophil
phagocyt
capac
also
observ
use
bacteria
viru
specif
properti
adefensin
suggest
potenti
templat
novel
therapeut
howev
abil
bind
surfact
protein
spd
may
concern
mix
competit
cooper
iav
straindepend
effect
antivir
activ
spd
hnp
bdefensin
bind
precipit
bronchoalveolar
lavag
bal
fluid
spd
may
account
spd
deplet
lung
diseas
chronic
neutrophil
inflamm
origin
suggest
adefensin
activ
nonenvelop
virus
basi
absenc
effect
echoviru
type
ii
reoviru
type
howev
recent
work
demonstr
inhibit
nonenvelop
virus
adenoviru
human
papillomaviru
hpv
bk
viru
mechan
underpin
antivir
effect
nonenvelop
virus
appear
distinct
target
envelop
virus
studi
hpv
utilis
pseudoviru
particl
found
normal
bind
uncoat
internalis
presenc
adefensin
howev
peptid
prevent
virion
escap
endocyt
vesicl
antivir
activ
observ
use
cathelicidin
maxim
use
observ
use
sensit
adenovirus
adefensinmedi
neutralis
serotypedepend
shown
inhibit
human
adenoviru
infect
lung
conjunctiv
epitheli
cell
inhibit
earli
step
viral
entri
two
arginin
residu
one
face
found
critic
antivir
activ
necessari
kill
adv
hpv
adv
viral
aggreg
suffici
neutralis
bind
adefensin
adenovir
viru
capsid
appear
critic
prevent
uncoat
cell
henc
entri
viral
genom
nucleu
contrast
antivir
effect
bk
polyomaviru
appear
primarili
relat
viral
aggreg
prevent
receptor
bind
host
cell
similarli
human
rhinoviru
hrv
replic
human
bronchial
epitheli
cell
induc
nfjbdepend
express
wherea
respiratori
syncyti
viru
rsv
induc
nfjbdepend
ifn
type
manner
human
lung
epitheli
cell
extent
innat
respons
function
effect
viral
pathogen
start
elucid
fig
contrast
effect
adefensin
one
bdefensin
test
appreci
effect
hsv
found
inhibit
infect
human
cervic
epitheli
cell
approxim
log
lgml
interf
viral
bind
penetr
process
bind
gb
heparan
sulphat
contrast
low
affin
gb
cellular
glycosaminoglycan
abl
reduc
infect
howev
appli
vivo
studi
infect
epitheli
cell
induc
express
vitro
buccal
mucos
cell
vivo
inhibit
hiv
transmiss
multipl
mechan
downregul
coreceptor
express
surfac
cell
via
increas
internalis
addit
direct
effect
virion
concentrationdepend
manner
intracellular
postvir
entri
inhibit
howev
largescal
studi
copi
number
variat
total
bdefensin
gene
number
posit
correl
hiv
load
ethiopian
tanzanian
patient
author
suggest
chemoattract
natur
bdefensin
may
bring
target
cell
mucos
site
readili
infect
viru
work
howev
recent
shown
expos
seroneg
individu
much
higher
copi
number
oral
mucosa
vagin
mucosa
healthi
control
indic
role
defensin
combat
infect
although
normal
regard
induc
express
observ
primari
human
bloodderiv
plasmacytoid
dc
monocyt
follow
infect
iav
contrast
earli
decreas
express
peptid
found
iavinfect
epitheli
cell
line
recombin
found
antivir
effect
vitro
approxim
log
decreas
lgml
howev
despit
evid
signific
defect
host
defenc
iav
mice
extend
differ
viral
load
suggest
primari
role
immunomodulatori
properti
vivo
iav
found
upregul
express
murin
defensin
upper
lower
airway
well
transcript
gene
encod
lung
also
suggest
protect
role
peptid
recombin
protect
mdck
cell
infect
iav
strain
approxim
log
decreas
lgml
protect
effect
bind
internalis
viru
viral
entri
furthermor
repeat
intranas
administr
recombin
mgkg
optim
premix
viru
infect
intraven
deliveri
recombin
mgkg
found
protect
murin
lethal
infect
model
latter
studi
also
suggest
effect
may
relat
immunomodulatori
properti
system
treatment
upregul
ifnc
reduc
level
tnf
thu
although
bdefensin
inhibit
influenza
viru
infect
albeit
less
potent
adefensin
immunomodulatori
properti
perhap
also
includ
upregul
iav
uptak
neutrophil
may
prove
key
protect
function
viru
vivo
futur
therapeut
develop
addit
effect
iav
evid
found
bdefensin
activ
rsv
anoth
import
respiratori
viru
effect
vaccin
antivir
treatment
exist
studi
use
human
lung
cell
line
identifi
compon
nfjbdepend
ifnabindepend
antivir
respons
epitheli
cell
product
induc
respons
rsv
replic
also
respons
tnf
secret
infect
epitheli
cell
found
protect
rsv
infect
approxim
log
decreas
lgml
block
viral
cellular
entri
destabilis
viral
envelop
propos
occur
upon
contact
solubl
solut
follow
exposur
plasma
membraneassoci
cell
entri
addit
lung
epitheli
cell
myeloid
cell
produc
high
level
tnf
respons
rsv
infect
potenti
upregul
express
airway
lumen
might
consequ
modul
protect
rsv
infect
limit
viru
spread
interestingli
consid
homologu
found
upregul
vivo
murin
lung
respons
rsv
infect
propos
antivir
activ
vaccinia
viru
howev
unabl
neutralis
viru
preexposur
viru
synthet
h
decreas
infect
monkey
kidney
cell
line
shown
reduc
level
dnadepend
rna
polymeras
express
plaqu
format
approxim
log
decreas
lm
although
mechan
remain
elucid
upregul
express
observ
respons
vaccinia
viru
infect
primari
human
keratinocyt
could
inhibit
interestingli
cytokin
associ
patholog
atop
dermat
condit
bdefensin
express
reduc
patient
risk
develop
eczema
vaccinatum
caus
vaccinia
viru
circular
hdefensin
identifi
leukocyt
bone
marrow
macaqu
rhesu
hdefensin
rtd
discov
effect
antibacteri
activ
human
found
least
six
hdefensin
gene
deft
gene
none
produc
translat
protein
owe
insert
prematur
stop
codon
put
ancestr
human
hdefensin
name
retrocyclin
rc
develop
antimicrobi
properti
test
addit
activ
pseudomona
aeruginosa
e
coli
listeria
monocytogen
staphylococcu
aureu
antivir
potenti
also
describ
fig
rhesu
hdefensin
retrocyclin
includ
found
inhibit
infect
human
cervic
epitheli
cell
line
follow
preincub
viru
peptid
howev
found
direct
virucid
properti
activ
irrespect
preincub
block
attach
cell
penetr
hsv
activ
result
peptid
bind
manner
depend
presenc
sialic
acid
carbohydr
moieti
glycoprotein
oand
nlink
glycan
prophylact
applic
murin
hsvmediat
ocular
kerat
model
demonstr
capac
modestli
reduc
viral
titr
vivo
reduc
blephar
corneal
vascular
stromal
diseas
howev
effect
upon
diseas
patholog
appli
postinfect
initi
studi
retrocyclin
found
direct
inactiv
demonstr
strong
inhibit
provir
dna
format
protect
primari
human
cell
tand
mtropic
strain
vitro
observ
led
signific
bodi
work
evalu
retrocyclin
hiv
treatment
characteris
lectin
protect
peripher
blood
peptid
prevent
viral
entri
cell
block
format
bundl
requir
fusion
bind
hiv
cellular
interact
oand
nlink
sugar
activ
mani
initi
retrocyclin
produc
inhibit
serum
minimis
use
serumcontain
anatom
compart
howev
analogu
differ
singl
amino
acid
substitut
show
greater
potenti
topic
microbicid
found
inhibit
primari
cell
infect
similarli
activ
presenc
vagin
fluid
significantli
potent
hiv
potenti
topic
microbicid
interestingli
rate
escap
mutat
hiv
low
treatment
alter
site
reduc
suscept
compar
blockad
use
organ
cultur
model
found
block
transmiss
two
strain
across
cervic
mucosa
antivir
activ
retain
presenc
semen
vagin
fluid
cytotox
cervic
tissu
importantli
induc
proinflammatori
respons
chemotact
activ
immun
cell
addit
topic
intravagin
applic
pigtail
macaqu
found
safe
well
toler
peptid
retain
cervic
vagin
tissu
day
postappl
chang
vagin
ph
observ
minim
effect
commens
microbiota
applic
retrocyclin
pathogen
respiratori
virus
also
evalu
express
recombin
mdck
cell
chicken
embryo
shown
inhibit
replic
influenza
viru
addit
antivir
activ
studi
use
mdck
cell
line
approxim
log
decreas
lgml
iav
less
effect
strain
retrocyclin
effect
potenc
equival
studi
note
capac
rc
peptid
induc
aggreg
viru
increas
viral
uptak
neutrophil
macrophag
also
found
inhibit
influenza
infect
cell
line
vitro
block
haemagglutininmedi
fusion
viral
endosom
membran
inhibit
hemifus
format
shown
lectin
properti
involv
cross
link
immobilis
surfac
glycoprotein
block
protein
displac
requir
bridg
bilay
fusion
effect
given
viral
internalis
antivir
properti
even
appli
host
cell
membran
interestingli
despit
capac
bind
spd
retrocyclin
increas
rather
inhibit
antivir
activ
spd
contrast
adefensin
promis
therapeut
use
mucos
site
improv
antivir
activ
synthet
retrocyclin
influenza
simplifi
structur
seri
analogu
contain
amino
acid
term
hapivirin
diprovirin
design
analogu
includ
dpv
prove
effect
iav
mechanist
analog
retrocyclin
peptid
found
activ
viral
internalis
induc
viral
aggreg
opsonis
viru
addit
effect
spd
addit
hapivirin
diprovirin
shown
inhibit
iavinduc
macrophag
tnf
product
ad
immunomodulatori
mechan
therapeut
potenti
antivir
activ
retrocyclin
also
report
sar
viru
coronaviru
infect
alveolar
epitheli
cell
induc
rapid
sever
lung
patholog
mous
model
sar
infect
treatment
increas
surviv
interestingli
absenc
impact
viral
titr
instead
cytokin
profil
infect
anim
modifi
increas
earli
day
product
gmcsf
decreas
day
data
highlight
possibl
novel
peptid
therapeut
may
product
target
modul
inflammatori
respons
infect
rather
develop
virucid
properti
per
se
approach
may
prove
broadspectrum
applic
lend
support
potenti
peptid
novel
immunomodulatori
antivir
agent
cathelicidin
wide
studi
regard
antibacteri
properti
broad
array
immunomodulatori
activ
although
known
upregul
inflamm
releas
neutrophil
role
defenc
viral
infect
properti
antivir
agent
less
well
understood
fig
express
human
epididym
epithelium
present
high
concentr
semin
plasma
also
express
cervicovagin
secret
upregul
particip
bacteri
sexual
transmit
infect
cervicovagin
level
hivneg
individu
hiv
serodiscord
relationship
also
found
greatest
whose
hivposit
partner
highest
viral
load
shown
inhibit
replic
rang
isol
primari
cell
occur
manner
independ
chang
express
receptor
cell
recent
studi
demonstr
capabl
dosedepend
suppress
hiv
revers
transcriptas
activ
studi
also
demonstr
function
retain
amino
acid
fragment
implic
product
smaller
synthet
analogu
thu
epitheli
express
propos
contribut
local
protect
infect
howev
although
cation
peptid
fraction
cervicovagin
secret
found
activ
could
enhanc
addit
recombin
properti
correl
level
endogen
detect
addit
one
studi
level
independ
associ
increas
hiv
acquisit
although
observ
might
result
high
preval
sexual
transmit
infect
individu
therefor
vivo
signific
hiv
remain
unclear
recent
demonstr
antivir
effect
iav
vitro
vivo
human
murin
cathelicidin
antivir
activ
preincub
influenza
virus
vitro
approxim
log
decreas
lgml
somewhat
less
effect
addit
recent
shown
bind
iav
without
aggreg
affect
haemagglutin
activ
maxim
effect
vitro
preincub
viru
although
delay
addit
peptid
treatment
cell
wash
infect
also
antivir
effect
surprisingli
found
alter
bind
initi
uptak
viru
cell
peptidemedi
disrupt
viral
membran
shown
electron
microscopi
propos
affect
viral
propag
surviv
downstream
demonstr
aerosolis
therapeut
administr
either
mcramp
given
everi
day
week
addit
preinfect
dose
provid
protect
infect
mous
model
peptidetr
mice
show
increas
surviv
decreas
weight
loss
compar
control
infect
anim
similarli
protect
treat
zanamavir
neuraminidas
inhibitor
current
use
therapeut
human
cathelicidintr
mice
show
decreas
viral
load
strike
reduct
lung
cytokin
particular
gmcsf
kc
suggest
possibl
key
immunomodulatori
role
antivir
efficaci
peptid
scrambl
control
peptid
effect
interestingli
denantiom
indic
action
sole
relat
charg
like
reliant
specif
receptor
interact
mechan
cathelicidin
modul
inflamm
iav
infect
remain
unclear
may
relat
observ
modul
tolllik
receptor
signal
induct
rapid
antivir
respons
depend
least
part
tlr
recognit
viral
genom
ssrna
dsrna
virus
recognis
complex
self
dna
rna
shown
induc
inflammatori
respons
otherwis
nonimmunostimulatori
nucleic
acid
addit
propos
enhanc
inhibit
respons
viral
rna
synthet
mimic
modulatori
properti
may
well
prove
underpin
vivo
effect
express
airway
epitheli
cell
induc
vitro
infect
rsv
manner
significantli
enhanc
metabolit
vitamin
addit
recent
studi
found
median
serum
level
significantli
lower
children
rsv
bronchiol
children
bronchiol
caus
human
rhinoviru
furthermor
rsvinfect
children
level
lower
median
like
hospitalis
prolong
period
level
median
find
suggest
import
antivir
role
host
innat
immun
respons
rsv
keep
hypothesi
recent
demonstr
exhibit
effect
dosedepend
timingspecif
antirsv
activ
vitro
number
cell
line
data
indic
therapeut
use
cathelicidin
strategi
upregul
cathelicidin
express
vivo
particularli
winter
low
vitamin
level
may
lead
diminish
cathelicidin
express
may
protect
rsv
infect
individu
atop
dermat
ad
low
level
express
increas
suscept
skin
infect
contrast
psoriasi
high
level
express
less
prone
skin
infect
despit
similar
disrupt
skin
barrier
function
low
level
express
ad
propos
import
suscept
eczema
vaccinatum
dissemin
viral
skin
infect
follow
inocul
vaccinia
viru
vv
express
induc
respons
vv
normal
psoriat
skin
biopsi
ad
skin
mcramp
shown
antivir
activ
vaccinia
viru
vitro
approxim
log
decreas
lm
peptid
shown
damag
integr
doublelay
viral
envelop
remov
outer
membran
addit
campmic
found
develop
significantli
pox
skin
lesion
follow
infect
vv
demonstr
antivir
effect
cathelicidin
vivo
interestingli
effect
vv
found
specif
cathelicidin
unabl
neutralis
viru
impli
differ
chdp
may
differ
sometim
overlap
target
order
success
deal
enorm
wide
rang
human
pathogen
antivir
activ
host
defenc
peptid
somewhat
neglect
recent
contrast
studi
antibacteri
effect
yet
discuss
review
strong
basi
exist
futur
evalu
physiolog
role
chdp
key
compon
innat
antivir
host
defenc
develop
synthet
analogu
novel
antivir
therapeut
precis
mechan
involv
clearli
vari
peptideand
virusspecif
manner
direct
effect
virus
primarili
immunomodulatori
properti
need
examin
detail
test
vivo
specif
viral
infect
research
expect
reveal
therapeut
strategi
rang
simpl
administr
potent
antivir
andor
immunomodulatori
analogu
therapeut
measur
enhanc
natur
level
express
replac
downregul
peptid
provid
peptid
earlier
critic
tip
point
stage
infect
although
peptid
may
prove
effect
administ
infect
establish
optim
use
peptid
therapeut
may
prophylact
administr
highrisk
popul
eg
infant
elderli
outbreak
novel
influenza
strain
vaccin
avail
challeng
remain
optimis
peptid
therapeut
develop
shortest
cheapest
analogu
stabl
function
lower
concentr
physiolog
environ
without
cytotox
effect
gener
resist
regard
hdefensin
appear
particularli
excit
potenti
topic
antihiv
agent
well
toler
certain
member
famili
appear
function
presenc
serum
rapidli
directli
kill
without
induc
largescal
immun
activ
escap
variant
infrequ
engin
peptid
simpl
process
enabl
develop
suitabl
compound
differ
antivir
capabl
rc
valu
despit
differ
singl
amino
acid
hint
possibl
engin
singl
amino
acid
chang
lead
significantli
higher
activ
also
suggest
enhanc
possibl
likewis
linear
disulphid
bondfre
defensin
gener
retain
potent
antimicrobi
activ
develop
linear
peptid
would
significantli
easier
recreat
tertiari
structur
howev
stabil
peptid
proteas
degrad
remain
uncertain
loss
antivir
properti
follow
linearis
describ
instanc
highlight
need
research
thu
era
increas
concern
resurg
threat
infecti
diseas
limit
repertoir
antivir
drug
fear
rapid
new
virus
spread
global
peptid
therapeut
potenti
clearli
worth
pursu
acknowledg
djd
support
mrc
senior
nonclin
research
fellowship
smc
support
univers
edinburgh
colleg
medicin
veterinari
medicin
studentship
author
conflict
interest
directli
relev
content
articl
open
access
articl
distribut
term
creativ
common
attribut
noncommerci
licens
permit
noncommerci
use
distribut
reproduct
medium
provid
origin
author
sourc
credit
exclus
right
commerci
use
articl
springer
